, Volume 21, Issue 1, pp 47–59 | Cite as

MVA E2 Recombinant Vaccine in the Treatment of Human Papillomavirus Infection in Men Presenting Intraurethral Flat Condyloma

A Phase I/II Study
  • Antonio Albarran y Carvajal
  • Alfonso de la Garza
  • Benitez Jose Cecilio Cruz Quiroz
  • Eduardo Vazquez Zea
  • Ismael Díaz Estrada
  • Ernesto Mendez Fuentez
  • Mario López Contreras
  • Alejandro Andrade-Manzano
  • Santiago Padilla
  • Axel Ramírez Varela
  • Ricardo Rosales
Original Research Article



Human papillomavirus (HPV) is the etiologic agent for warts and cervical cancer. In Mexico, the death rate from cervical cancer is extremely high, and statistical data show that since 1990 the number of deaths is increasing. Condylomas and cancer of the penis are the most common lesions presented in men; bladder and prostate cancer in men are also associated with the presence of HPV. Since HPV is transmitted by sexual intercourse, treating both partners is necessary in order to eliminate the virus in the population. Approaches to this include preventative vaccines such as Gardasil®, and therapeutic vaccines to treat established infections in both men and women. This will be the only way to decrease the numbers of deaths due to this malignancy.

Patients and methods

We conducted a phase I/II clinical trial to evaluate the potential use of the recombinant vaccinia viral vaccine MVA E2 (composed of modified vaccinia virus Ankara [MVA] expressing the E2 gene of bovine papillomavirus) to treat flat condyloma lesions associated with oncogenic HPV in men. Fifty male patients with flat condyloma lesions were treated with either MVA E2 therapeutic vaccine or fluorouracil (5-fluorouracil). Thirty men received the therapeutic vaccine, at a total of 106 virus particles per dose, administered directly into the urethra once every week over a 4-week period. Twenty control patients were treated with 5% fluorouracil 1mL twice weekly over a 4-week period directly into the urethra. Reduction of lesions or absence of papillomavirus infection was monitored by colposcopy and histologic analysis. The immune response after MVA E2 treatment was determined by measuring the antibodies against the MVA E2 virus and by analyzing the lymphocyte cytotoxic activity against cancer cells bearing oncogenic papillomavirus. Presence of papillomavirus was determined by the Hybrid Capture® method.


Twenty-eight of 30 patients showed no lesion or presence of papillomavirus as diagnosed by colposcopy and brush histologic examination after 4 weeks of MVA E2 treatment. These patients showed complete elimination of flat condyloma in the urethra and no acetowhite spots were detected over the prepuce. In two other patients the acetowhite spots and flat condyloma did not diminish. All patients developed antibodies against the MVA E2 vaccine and E2 protein, and generated a specific cytotoxic response against papilloma-transformed cells. Viral DNA was not detected in MVA E2-treated patients.

In the control group, 13 of 20 patients were free of lesions. Three of these patients had recurrence of lesions after 3 months of treatment and none of the patients developed specific antibodies against cancer cells. In contrast, patients treated with MVA E2 did not show any recurrence of lesions after 1 year of treatment. In addition, none of the patients had local or systemic adverse effects according to the WHO classification 1–4.


Therapeutic vaccination with MVA E2 proved to be very effective in stimulating the immune system against papillomavirus, and in generating regression of flat condyloma lesions in men.


Cervical Cancer Genital Wart Therapeutic Vaccine Modify Vaccinia Virus Ankara Chicken Embryo Fibroblast Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This work was funded by Virolab, S de RL de CV. The authors declare no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    Dürst M, Gissmann L, Ikenberg H, et al. Papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 1983; 80: 3812–5PubMedCrossRefGoogle Scholar
  2. 2.
    Muñoz N, Bosch FX, de Sanjosé S. The causal link between human papillomavirus and invasive cervical cancer: a population study based in Colombia and Spain. Int J Cancer 1992; 52: 743–9PubMedCrossRefGoogle Scholar
  3. 3.
    Munoz N, Bosch FX. Cervical cancer and human papillomavirus: epidemiological evidence and perspectives for prevention. Salud Publica Mex 1997; 39: 274–82PubMedCrossRefGoogle Scholar
  4. 4.
    Vallejos H, Del Mistro A, Kleinhaus S, et al. Characterization of human papillomavirus types in condylomata acuminata in children by in situ hybridization. Lab Invest 1987; 56: 611–5PubMedGoogle Scholar
  5. 5.
    zur Hausen H. Papillomavirus in anogenital cancer: the dilemma of epidemiologic approaches. J Natl Cancer Inst 1989; 81: 1680–1PubMedCrossRefGoogle Scholar
  6. 6.
    Kjaer S, Munk C, Winther J, et al. Acquisition and persistence of human papillomavirus infection in younger men: a prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 2005; 14: 1528–33PubMedCrossRefGoogle Scholar
  7. 7.
    Mayeaux EJ, Harper M, Barksdale W, et al. Noncervical human papillomavirus genital infections. Am Fam Physician 1995; 52: 1137–46PubMedGoogle Scholar
  8. 8.
    Lazcano-Ponce E, Herrero R, Munoz N, et al. High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples. Sex Transm Dis 2001; 28: 277–80PubMedCrossRefGoogle Scholar
  9. 9.
    Grussendorf-Conen E, de Villiers E, Gissmann L. Human papillomavirus genomes in penile smears of healthy men. Lancet 1986; 8: 1092CrossRefGoogle Scholar
  10. 10.
    Beltran López A, Escudero A. Human papillomavirus and bladder cancer. Biomed Pharmacother 1997; 51: 252–7CrossRefGoogle Scholar
  11. 11.
    Brown T, Yen-Moore A, Tyring S. An overview of sexually transmitted diseases: part II. Am J Dermatopathol 1999; 41: 661–77Google Scholar
  12. 12.
    Dillner J, Meijer C, von Krogh G, et al. Epidemiology of human papillomavirus infection. Scand J Urol Nephrol 2000; 205: 194–200CrossRefGoogle Scholar
  13. 13.
    Malizia M, Ntreta M, Galupi A, et al. A case tumor of the penis: interstitial brachitherapy after conservative surgical therapy. Arch Ital Urol Androl 2004; 76: 177–8PubMedGoogle Scholar
  14. 14.
    Pow-Sang M, Benavente V, Pow-Sang JE, et al. Cancer of the penis. Cancer Control 2003; 9: 305–10Google Scholar
  15. 15.
    von Krogh G, Horenblas S. Diagnosis and clinical presentation of premalignant lesions of the penis. Scand J Urol Nephrol 2000; 205: 201–14CrossRefGoogle Scholar
  16. 16.
    Fisher B, Margesson L. Genital skin disorders. St Louis (MO): Mosby, 1998Google Scholar
  17. 17.
    Moscicki A. Genital human papillomavirus infections in children and adolescents. Curr Probl Dermatol 2000; 28: 134–40CrossRefGoogle Scholar
  18. 18.
    Cardamakis E, Relakis K, Ginopoulos P, et al. Treatment of penile intraepithelial neoplasia (PIN) with interferon alpha-2a, CO2 laser (vaporization) and 5-fluoruracil 5% (5-FU). Eur J Gynaecol Oncol 1997; 18: 410–3PubMedGoogle Scholar
  19. 19.
    Severson J, Evans T, Lee P, et al. Human papillomavirus infections: epidemiology, pathogenesis and therapy. J Cutan Med Surg 2001; 5: 43–60PubMedGoogle Scholar
  20. 20.
    Kodner C, Nasraty S. Management of genital warts. Am Fam Phys 2004; 70: 2335–45Google Scholar
  21. 21.
    Burmer G, True L, Krieger J. Squamous cell carcinoma of the scrotum associated with human papillomavirus. J Urol 1993; 149: 374–7PubMedGoogle Scholar
  22. 22.
    Spano J, Marcelin A, Carcelin G. HPV and cancer. Bull Cancer 2005; 92: 59–64PubMedGoogle Scholar
  23. 23.
    Taylor M, Mainous III A, Wells B. Prostate cancer and sexually transmitted diseases: a meta-analysis. Fam Med 2005; 37: 506–13PubMedGoogle Scholar
  24. 24.
    Elsässeer-Beile U, Leiber C, Wolf P, et al. Adjuvant intravesical treatment of superficial bladder cancer with a standardized mistletoe extract. J Urol 2005; 174: 76–9CrossRefGoogle Scholar
  25. 25.
    Schmiedeskamp M, Kockler D. Human papillomavirus vaccines. Ann Pharmacother 2006; 40: 1344–52PubMedCrossRefGoogle Scholar
  26. 26.
    Borysiewicz LK, Fiander A, Nimako M, et al. A Recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as Immunotherapy for cervical cancer. Lancet 1996; 347: 1523–7PubMedCrossRefGoogle Scholar
  27. 27.
    Galloway DA. Papillomavirus oncoproteins as vaccine candidates. Lancet 1996; 347: 1498–9PubMedCrossRefGoogle Scholar
  28. 28.
    Hall H, Teuscher C, Urie P, et al. Induced regression of bovine papillomas by intralesional immunotherapy. Ther Immunol 1994; 1: 319–24PubMedGoogle Scholar
  29. 29.
    Koutsky L, Ault K, Weeler C, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645–51PubMedCrossRefGoogle Scholar
  30. 30.
    Lowy DR, Schiller JT. Papillomaviruses: prophylactic vaccine prospects. Biochem Biophys Acta 1999; 1423: M1–8PubMedGoogle Scholar
  31. 31.
    Rosales C, Valadez G, Arrellin R, et al. A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity. Cancer Immunol Immunother 2000; 49: 347–60PubMedCrossRefGoogle Scholar
  32. 32.
    Fenner F, Henderson DA, Arita I, et al. Smallpox and its eradication. Geneva: WHO, 1988: 539–92Google Scholar
  33. 33.
    Mayr A, Hochstein-Mintzel V, Stickl H. Abstammung, Eigenschaften, und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 1975; 3: 6–14CrossRefGoogle Scholar
  34. 34.
    Mayr A, Stickl H, Muller HK, et al. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism [in German]. Zentralbl Bakteriol [B] 1978; 167: 375–90Google Scholar
  35. 35.
    Stickl H, Hochstein-Mintzel V, Mayr A, et al. MVA-Stufenimpfung gegen Pocken. Dtsch Med Wochenschr 1974; 99: 2386–92PubMedCrossRefGoogle Scholar
  36. 36.
    Werner GT, Jentsch U, Metzger E, et al. Studies on poxvirus infection in irradiated animals. Arch Virol 1980; 64: 247–56PubMedCrossRefGoogle Scholar
  37. 37.
    Hochstein-Mintzel V, Huber HC, Stickl H. Virulenz und Immunogenität eines modifizierten vaccinia-Virus (Stamm MVA). Z Immunitasforsch Exp Klin Immunol 1972; 144: 140–5Google Scholar
  38. 38.
    Hanke T, Blanchard TJ, Schneider J, et al. Immunogenicities of intravenous and intramuscular administration of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virys type 1 in mice. J Gene Virol 1998; 79: 83–90Google Scholar
  39. 39.
    Degano P, Schneider J, Hannan CM, et al. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 1999; 18: 623–32PubMedCrossRefGoogle Scholar
  40. 40.
    Huemer HP, Strobl B, Nowotny N. Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme. Vaccine 2000; 18: 1320–6PubMedCrossRefGoogle Scholar
  41. 41.
    Men R, Wyatt L, Tokimatsu I, et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of Dengue type 2 virus induced resistance to dengue type 2 virus challange. Vaccine 2000; 18: 3113–22PubMedCrossRefGoogle Scholar
  42. 42.
    Stittelaar K, Wyatt L, de Swart R, et al. Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. J Virol 2000; 74: 4236–43PubMedCrossRefGoogle Scholar
  43. 43.
    Wyatt L, Shors S, Murphy B, et al. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine 1996; 14: 1451–8PubMedCrossRefGoogle Scholar
  44. 44.
    Weidinger G, Ohlmann M, Schlereth B, et al. Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model. Vaccine 2001; 19: 2764–8PubMedCrossRefGoogle Scholar
  45. 45.
    Dowhanick JJ, McBride AA, Howley PM. Supression of cellular proliferation by the papillomavirus E2 protein. J Virol 1995; 69: 7791–9PubMedGoogle Scholar
  46. 46.
    Desaintes C, Demeret C, Goyat S, et al. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997; 16: 504–14PubMedCrossRefGoogle Scholar
  47. 47.
    Valadez G, Sutter G, Jose M, et al. Human tumor growth is inhibited by vaccinia virus carrying the E2 gene of bovine papillomavirus. Cancer 2000; 88: 1650–62CrossRefGoogle Scholar
  48. 48.
    Corona-Gutierrez C, Tinoco A, Contreras M, et al. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 2002; 13: 1127–40PubMedCrossRefGoogle Scholar
  49. 49.
    Corona-Gutierrez C, Tinoco A, Navarro T, et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2 and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 2004; 15: 421–31PubMedCrossRefGoogle Scholar
  50. 50.
    Sutter G, Moss B. Non replicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992; 89: 10847–1085PubMedCrossRefGoogle Scholar
  51. 51.
    Falkner FG, Moss B. Echerichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol 1988; 62: 1849–54PubMedGoogle Scholar
  52. 52.
    WHO. Bulletin 211. Wkly Epidemiol Rec 1986; 64: 607Google Scholar
  53. 53.
    Geipert N. Vaccinating men for HPV: new strategy for preventing cervical cancer in women? J Natl Cancer Inst 2005; 97: 630–1PubMedCrossRefGoogle Scholar
  54. 54.
    Binns MM, Smith GL. Recombinant poxvirus. Boca Raton (FL): ACR Press, 1993Google Scholar
  55. 55.
    Perkus ME, Piccini A, Lipinskas BR, et al. Recombinant vaccinia virus: immunization against multiple pathogens. Science 1985; 229: 981–4PubMedCrossRefGoogle Scholar
  56. 56.
    Cardamakis E, Kotoulas I, Metalinos K, et al. Treatment of urethral condylomata acuminata or flat condylomata with interferon-alpha 2a. J Urol 1994; 152: 2011–3PubMedGoogle Scholar
  57. 57.
    Carpiniello V, Schoenberg M, Malloy T. Long-term followup of subclinical human papillomavirus infection treated with the carbon dioxide laser and intraurethral 5-fluoruracil: a treatment protocol. J Urol 1990; 143: 726–8PubMedGoogle Scholar
  58. 58.
    Eder J, Kantoff P, Roper K, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6: 1632–8PubMedGoogle Scholar
  59. 59.
    Hodge JW, Poole DJ, Aarts WM, et al. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 2003; 63: 7942–9PubMedGoogle Scholar
  60. 60.
    Chen C, Wang T, Hung C, et al. Boosting with recombinant vaccinia virus increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. Vaccine 2000; 18: 2015–22PubMedCrossRefGoogle Scholar
  61. 61.
    Van der Burg S, Kwappenberg K, O'Neil T, et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine in homologous and heterologous prime-boost regimes. Vaccine 2001; 19: 3652–60PubMedCrossRefGoogle Scholar
  62. 62.
    Ault K, Giuliano A, Edwards R, et al. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 2004; 22: 3004–7PubMedCrossRefGoogle Scholar
  63. 63.
    Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757–65PubMedCrossRefGoogle Scholar
  64. 64.
    Lowy D, Schiller J. Prophylactic human papillomavirus vaccines. J Clin Invest 2006; 116: 1167–73PubMedCrossRefGoogle Scholar
  65. 65.
    Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006; 61: 13–4CrossRefGoogle Scholar
  66. 66.
    Weaver B. Epidemiology and natural history of genital human papillomavirus infection. J Am Osteopath Assoc 2006; 106: S2–8PubMedGoogle Scholar
  67. 67.
    Bergman A, Nalick R. Genital human papillomavirus infection in men: diagnosis and treatment with a laser and 5-fluoruracil. J Reprod Med 1991; 36: 363–6PubMedGoogle Scholar
  68. 68.
    Stockfleth E, Rowert J, Arndt R, et al. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol 2000; 143: 846–50PubMedCrossRefGoogle Scholar
  69. 69.
    Ramirez J, Gherardi M, Rodriguez D, et al. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000; 74: 7651–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Antonio Albarran y Carvajal
    • 1
  • Alfonso de la Garza
    • 1
  • Benitez Jose Cecilio Cruz Quiroz
    • 1
  • Eduardo Vazquez Zea
    • 1
  • Ismael Díaz Estrada
    • 1
  • Ernesto Mendez Fuentez
    • 1
  • Mario López Contreras
    • 2
  • Alejandro Andrade-Manzano
    • 3
  • Santiago Padilla
    • 4
  • Axel Ramírez Varela
    • 5
  • Ricardo Rosales
    • 6
  1. 1.Hospital General de Tlalnepantla Clínica de DisplasiasValle CeylánMéxico
  2. 2.FES Zaragoza, National Autonomous University of MéxicoMéxico CityMéxico
  3. 3.Hospital de Gineco ObstetriciaInstituto Mexicano del Seguro Social (IMSS)México CityMéxico
  4. 4.Hospital de la MujerJacona, Zamora MichoacanMéxico
  5. 5.Hospital Juárez de MéxicoMéxico CityMéxico
  6. 6.Department of Molecular BiologyVirolab, S de RL de CVColonia LindavistaMexico

Personalised recommendations